Xalkori is being reviewed for ALK-positive ALCL. Credit: Nephron.

Pfizer has secured priority review from the US Food and Drug Administration (FDA) for Xalkori (crizotinib) to treat relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) in children.

If approved, Xalkori will become the first biomarker-driven therapy for paediatric ALK-positive ALCL, Pfizer said.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Xalkori, a tyrosine kinase inhibitor (TKI), is a treatment for patients with ALK-positive or ROS1-positive metastatic non-small cell lung carcinoma (NSCLC).

Pfizer submitted a supplemental new drug application (sNDA) seeking approval for the use of Xalkori in ALCL. The drug obtained breakthrough therapy designation (BTD) for ALK-positive ALCL indication in May 2018.

Study ADVL0912 and Study A8081013 backed the sNDA data, which demonstrated encouraging anti-tumour activity with Xalkori in children and adults with ALCL.

ADVL0912, a Phase I / II trial, analysed the maximum safe and tolerable dose, while also evaluating clinical activity in children with relapsed or refractory solid tumours and ALCL.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A8081013 assessed the use of Xalkori in paediatric and adult patients with advanced malignancies, including those with relapsed or refractory ALCL.

The sNDA comes after European Medicines Agency agreement on a Pediatric Investigational Plan (PIP) for the drug.

The FDA should decide on the drug’s sNDA by January.

Pfizer Global Product Development oncology chief development officer Chris Boshoff said: “Given Xalkori’s proven efficacy in ALK-positive lung cancer and activity seen in clinical trials investigating relapsed or refractory ALK- and ROS-1 positive anaplastic large cell lymphoma, if approved, Xalkori could represent an important step toward improving outcomes for children with this type of cancer.”

Earlier this month, the European Commission concluded talks with Pfizer and BioNTech for the supply of 200 million doses of their potential Covid-19 vaccine candidate to European Union Member States.